|
 |
AngiomaxThis page contains recent news articles, when available, and an overview of Angiomax but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Angiomax (when available) Angiomax directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release For treatment of heparin-induced thrombocytopenia Mechanism Of Action: Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. News Articles on Bivalirudin Medicines Co. Suing Teva, Pliva Again Over Patent - 04 Jan 2010 Specifically, it is suing over the '343' patent. Medicines is already involved in lawsuits with the same companies over a separate patent on Angiomax. ABC News Medicines Co. Buys Heart Drug From Pfizer: BioBuzz - Dec 23, 2009 ...s primary product is Angiomax, a blood thinner used by doctors during angioplasty and cardiac stenting procedures. However, Angiomax faces generic ... TheStreet.com The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 - Dec 15, 2009 The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® ... CNNMoney.com (press release) DotW: Last-Minute Shopping - Dec 23, 2009 TMC needs to add critical-care products to a portfolio threatened by next year's patent expiration of top seller Angiomax. ... The IN VIVO Blog (blog) Medicines Co. amps up Angiomax lobbying - Oct 23, 2009 ...s case, the full-court press isn't for reform, but for something much more specific: a patent extension on its anti-coagulant Angiomax. ... FiercePharma Medicines Company Reports Operating Results (10-Q) - Nov 9, 2009 US Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment ofpatients with unstable angina undergoing coronary ... GuruFocus.com Medicines Co. gets positive EU panel result - Oct 23, 2009 The European Medicines Agency will make a final decision on the potential approval. In the US, the drug is sold under the name Angiomax. Forbes Medicines Co. Q3 Loss Narrows; Cuts FY09 EPS View - Update - Oct 28, 2009 Angiomax US sales increased by 9% to $92.2 million from $85 million in the third quarter of 2008. Angiomax/Angiox international net revenue was $5.5 million ... RTT News The Medicines Company Reports Third Quarter 2009 Financial Results - Nov 1, 2009 Angiomax US sales increased by 9% to $92.2 million in the third quarter of 2009 compared to $85.0 million in the third quarter of 2008. ... PR-CANADA.net (press release) Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage - Nov 12, 2009 The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, ... CNNMoney.com (press release) Armey says he mastered dual roles of lobbyist, conservative leader - Oct 29, 2009 Armey's biggest client at DLA Piper, New Jersey drug maker Medicines Co., lobbied mostly to extend a patent on its blood thinner Angiomax, according to ... Dallas Morning News EC approves Merck, Schering-Plough merger; Swine flu market on the rise; - Oct 23, 2009 ...s case, the full-court press isn't for reform, but for something much more specific: a patent extension on its anti-coagulant Angiomax. ... FierceBiotech The Medicines Company Announces Positive CHMP Opinion for Angiox® (Bivalirudin ... - Oct 23, 2009 Angiox is marketed as Angiomax in the USA and other territories. About The Medicines Company The Medicines Company (Nasdaq: MDCO) is focused on advancing ... Reuters New approaches to eptifibatide administration - Nov 2, 2009 Patients with recent STEMI (<48 hours); visible thrombus; bivalirudin (Angiomax, The Medicines Company) treatment; unprotected left main; use of ablative or ... Cardiology Today The Medicines Company gibt positive Empfehlung des CHMP für Angiox ... - Oct 23, 2009 Angiox wird in den USA und anderen Territorien als Angiomax vermarktet. Ãœber The Medicines Company The Medicines Company (NASDAQ: MDCO) ist auf die ... Reuters —Aprobación basada en los datos del ensayo de referencia HORIZONS-AMI— - Oct 23, 2009 Angiox se comercializa como Angiomax en los Estados Unidos y otros territorios. El principal objetivo de The Medicines Company (Nasdaq: MDCO) es progresar ... Business Wire (press release) The Medicines Company annonce un avis favorable pour Angiox (Bivalirudine ... - Oct 23, 2009 Angiox est commercialisé sous le nom d`Angiomax aux Etats-Unis et dans d`autres territoires. A propos de The Medicines Company The Medicines Company (MDCO ... Reuters —Aprovação baseada nos dados do ensaio clÃnico de referência HORIZONS-AMI— - Oct 23, 2009 Angiox é comercializado como Angiomax nos EUA e em outras regiões. The Medicines Company (Nasdaq: MDCO) dedica-se ao avanço do tratamento de pacientes de ... Business Wire (press release) Medicineså…¬å?¸å®£å¸ƒï¼ŒCHMPæ ¸å‡†Angiox？ (比ä¼?å?¢å®š)用于接å?—急诊心è„?手术的心è„?ç—…å?‘作患者 - Oct 26, 2009 Angiox是美国和其他地区的商å“?å??为Angiomax。 Medicineså…¬å?¸(Nasdaq: MDCO)专注于为全ç?ƒåŒ»é™¢å¸‚场æ??供具有æˆ?本效益的创新è?¯ç‰©ï¼Œä»¥æ¤æŽ¨åŠ¨å?±é‡?患者的治疗。 ... 凤凰网 Medicineså…¬å?¸å®£ä½ˆï¼ŒCHMPæ ¸å‡†Angiox® (比ä¼?盧定) 用於接å?—急診心臟手術的心臟病發作患者 - Oct 26, 2009 Angiox在美國和其他地å?€çš„商å“?å??稱為Angiomax。 Medicineså…¬å?¸(Nasdaq: MDCO) 專注於為全ç?ƒé†«é™¢å¸‚å ´æ??供具有æˆ?本效益的創新藥物，以æ¤æŽ¨å‹•é‡?症患者的治療。 ... 中央通訊社 ザ・メディシンズ・カンパニーã€?欧州CHMPã?Œç·Šæ€¥æ‰‹è¡“ã‚’å?—ã?‘る心臓発作患者ã?¸ã?®Angiox ... - Oct 26, 2009 Angioxã?¯ç±³å›½ã??ã?®ä»–ã?®åœ°åŸŸã?§Angiomaxã?®å??称ã?§è²©å£²ã?•ã‚Œã?¦ã?„ã?¾ã?™ã€‚ ザ・メディシンズ・カンパニー（Nasdaq: MDCO）ã?¯ã€?é?©æ–°çš„ã?§ã€?コスト効果ã?®é«˜ã?„医薬å“?を世界ã?®ç—…院 ... Business Wire (press release) Brand Names/Synonyms: Angiomax is also known by the following brand names and/or synonymsAngiomax; Angiomax (Medicines Co or MDCO) Drug Category: Angiomax is categorized under the following by the FDA: Anticoagulants; Antithrombotic Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: FPRPGGGGNGDFEEIPEEYL |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |